2025-524921-42-00招募中1 期
A three-part first-in-human trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of GUB-UCN2 in healthy lean and obese participants and participants with T2D
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Gubra A/S
- 入组人数
- 220
- 试验地点
- 2
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Drug Development
Scientific
Gubra A/S
研究点 (2)
Loading locations...
相似试验
招募中
1 期
A first-in-human study to determine the safety and tolerability of different doses of GEH200520 Injection and GEH200521 (18F) Injection and their uses in positron emission tomography imaging for patients with cancer2024-515218-42-00GE Healthcare Limited50
已完成
1 期
A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS120, which is an Antibody medication, to be administered alone or with Pembrolizumab in Subjects with Advanced Malignancies2024-514777-22-00Invox Pharma Limited113
招募中
1 期
A Phase I trial to establish the safety and maximum tolerated dose of high-affinity autologous BCMA-targeting CAR-T cells in patients with relapsed and refractory B-cell malignancies (CARLOTTA01)2022-502831-20-00Technische Universitat Dresden16
招募中
1 期
A first study in humans testing the safety and effects of KUP-101A in patients with certain advanced solid cancers2025-522402-21-00Kupando GmbH21
尚未招募
1 期
Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric JunctionNCT07406984Beijing Immunochina Medical Science & Technology Co., Ltd.18